Client Direct Billing was Neogenomics’s largest product and service line in fiscal 2025, bringing in $518.84M of $727.33M (71%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Client Direct Billing | $370.71M | $428.90M | $475.44M | $518.84M |
| Commercial Insurance | $73.28M | $88.02M | $99.84M | $117.51M |
| Medicare & Other Government | $65.59M | $74.37M | $84.60M | $90.87M |
| Self-Pay | $157.00K | $350.00K | $681.00K | $114.00K |
| Total | $509.73M | $591.64M | $660.57M | $727.33M |
Neogenomics brought in $727.33M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 10.1% from $660.57M in fiscal 2024. Client Direct Billing was the largest at $518.84M (71.3%), ahead of Commercial Insurance at $117.51M (16.2%) and Medicare & Other Government at $90.87M (12.5%). The remaining line, Self-Pay, brought in $114.00K.
Compared with fiscal 2024, Commercial Insurance grew fastest, up 17.7% to $117.51M. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines grew from $509.73M to $727.33M, a compound annual growth rate of 12.6%. Client Direct Billing's share of the total fell from 72.7% to 71.3%.
Scenario, Previously Reported was Neogenomics’s largest revenue line in fiscal 2016, bringing in $244.08M of $243.66M (100%).
| Scenario | FY 2016 |
|---|---|
| Scenario, Previously Reported | $244.08M |
| Restatement Adjustment | -$419.00K |
| Total | $243.66M |
Neogenomics brought in $243.66M from its two revenue lines in fiscal 2016, the year ended December 31, 2016. Scenario, Previously Reported was the largest at $244.08M (100.2%).
The total is net of Restatement Adjustment, which took $419.00K off revenue in fiscal 2016.
Neogenomics (NEO) reports its revenue by product and service and by scenario. In fiscal 2025, Client Direct Billing was its largest product and service line, bringing in $518.84M (71.3% of the total), followed by Commercial Insurance at $117.51M (16.2%).
Client Direct Billing was Neogenomics' largest product and service line in fiscal 2025, bringing in $518.84M, or 71.3% of the $727.33M total across its four product and service lines.
Scenario, Previously Reported was Neogenomics' largest revenue line in fiscal 2016, bringing in $244.08M, or 100.2% of the $243.66M total across its two revenue lines.
Among Neogenomics' product and service lines that make up at least 2% of revenue, Commercial Insurance grew fastest in fiscal 2025, up 17.7% from $99.84M to $117.51M.
Every figure comes from Neogenomics' annual financial filings, as reported. Each line keeps the name Neogenomics gives it, and years follow its fiscal calendar.
Neogenomics' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.